Although Discovery Laboratories Inc. has plenty of financial resources for near-term operations, the Doylestown, Pa.-based company secured a $75 million equity facility that it can access over the next three years. (BioWorld Today)
Retaining U.S. marketing rights for itself, Acusphere Inc. signed a deal with Nycomed Group for the European rights to its lead product, AI-700. (BioWorld Today)
If there is a textbook formula for when to conduct a public offering, Pharmion Corp. might have followed it to the letter on Thursday, raising $220.8 million just six weeks after receiving FDA approval for Vidaza. (BioWorld Today)
